The impact of preoperative calcitonin screening on the prognosis of patients with medullary thyroid cancer: a retrospective multicenter cohort study-Reference-Cited by-同舟云学术

The impact of preoperative calcitonin screening on the prognosis of patients with medullary thyroid cancer: a retrospective multicenter cohort study

Published:2024-06-04 Issue:2 Volume:85 Page:827-836
ISSN:1559-0100
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Hou Yingtong,Yang Yu,Chen Gang,Long Jianyan,He Yufei,Xiong Dandan,Pang Yuyan,Li Qi,Dong Guojie,Qiao Siqi,Chen Wenke,Li Xuyang,Zhang Jiayuan,Xu Tianyi,Chen Xinwen,Lai Fenghua,Guan Haixia,Lin Bo,Liu Yihao

Funder

Research Fund of Medical Science and Technology of Guangdong Province

National Natural Science Foundation of China

Guangzhou Science and Technology Project

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12020-024-03897-y.pdf

Reference38 articles.

1. P. Siironen, J. Hagstrom, H.O. Maenpaa, J. Louhimo, J. Arola, C. Haglund, Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma. Acta Oncol. 55(3), 357–364 (2016). https://doi.org/10.3109/0284186X.2015.1070963

2. F.D. Gilliland, W.C. Hunt, D.M. Morris, C.R. Key, Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79(3), 564–573 (1997). https://doi.org/10.1002/(sici)1097-0142(19970201)79:3

3. S.A. Wells Jr, S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel, N. Lee, A. Machens, J.F. Moley, F. Pacini, F. Raue, K. Frank-Raue, B. Robinson, M.S. Rosenthal, M. Santoro, M. Schlumberger, M. Shah, S.G. Waguespack; Carcinoma American Thyroid Association Guidelines Task Force on Medullary Thyroid, Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6), 567–610 (2015). https://doi.org/10.1089/thy.2014.0335

4. R.I. Haddad, L. Bischoff, D. Ball, V. Bernet, E. Blomain, N.L. Busaidy, M. Campbell, P. Dickson, Q.Y. Duh, H. Ehya, W.S. Goldner, T. Guo, M. Haymart, S. Holt, J.P. Hunt, A. Iagaru, F. Kandeel, D.M. Lamonica, S. Mandel, S. Markovina, B. Mciver, C.D. Raeburn, R. Rezaee, J.A. Ridge, M.Y. Roth, R.P. Scheri, J.P. Shah, J.A. Sipos, R. Sippel, C. Sturgeon, T.N. Wang, L.J. Wirth, R.J. Wong, M. Yeh, C.J. Cassara, S. Darlow, Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc Netw. 20(8), 925–951 (2022). https://doi.org/10.6004/jnccn.2022.0040

5. S. Filetti, C. Durante, D. Hartl, S. Leboulleux, L.D. Locati, K. Newbold, M.G. Papotti, A. Berruti; and Esmo Guidelines Committee. Electronic Address: Clinicalguidelines@Esmo.Org, Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann. Oncol. 30(12), 1856–1883 (2019). https://doi.org/10.1093/annonc/mdz400